Valuation: BioCardia Inc

Market Cap 11.55M 10.13M 9.35M 8.64M 16.37M 1.11B 16.7M 112M 43.67M 541M 43.36M 42.41M 1.88B P/E 2026 *
-1.49x
P/E 2027 * -1.93x
Enterprise Value 11.55M 10.13M 9.35M 8.64M 16.37M 1.11B 16.7M 112M 43.67M 541M 43.36M 42.41M 1.88B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
77%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 31/12/2001
Director of Finance/CFO 62 29/02/2016
Chief Tech/Sci/R&D Officer - 31/07/2017
Director TitleAgeSince
Director/Board Member 59 31/12/2001
Director/Board Member 72 31/12/2010
Chairman 90 31/12/2001
Date Insider Type Main position Quantity % Market Cap.
06-28Free

Chief Executive Officer

110,625 0.9726%
06-28Free

Executive/Senior Manager

39,521 0.3474%
06-28Free

Chief Financial Officer

60,483 0.5317%
Change 5-day change 1-year change 3-year change Capi.($)
-1.53%+0.78%+72.33%+127.47% 57.72B
-2.45%-7.32%+65.23%+83.15% 52.65B
+2.79%+8.63%+20.90%+469.75% 24.46B
-1.60%-1.25%-16.94%-13.66% 23.84B
-3.05%+3.06%+42.36%-5.66% 19.28B
-0.24%+5.11%+38.76%-25.95% 17.8B
+2.34%+14.18%+220.96%+380.99% 17.29B
-6.73%+9.90%+36.04% - 15.28B
-2.16%+3.48%+28.34%+192.82% 14.35B
Average -1.40%+5.20%+56.44%+151.11% 26.96B
Weighted average by Cap. -1.41%+2.71%+57.69%+139.32%

Financials

2026 *2027 *
Net sales - -
Net income -9.07M -7.96M -7.35M -6.79M -12.87M -869M -13.12M -88.31M -34.31M -425M -34.07M -33.32M -1.48B -10.02M -8.78M -8.11M -7.49M -14.2M -959M -14.49M -97.49M -37.88M -469M -37.61M -36.79M -1.63B
Net Debt - -
Logo BioCardia Inc
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-